



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |  |  |   |
|---|--|--|---|
| (51) International Patent Classification <sup>6</sup> :<br><b>A61B 5/00, 5/103</b>  |  | <b>A1</b>  | (11) International Publication Number: <b>WO 98/24360</b>           |
|   |  |  | (43) International Publication Date: <b>11 June 1998 (11.06.98)</b> |
| <p>(21) International Application Number: <b>PCT/CA97/00919</b></p> <p>(22) International Filing Date: <b>4 December 1997 (04.12.97)</b></p> <p>(30) Priority Data:<br/>2,192,036                  4 December 1996 (04.12.96)          CA</p> <p>(71)(72) Applicants and Inventors: LUI, Harvey [CA/CA]; 3415 West 11th Avenue, Vancouver, British Columbia V6R 2K1 (CA). ZENG, Haishan [CA/CA]; 11786 85B Avenue, Delta, British Columbia V4C 2W2 (CA). MacAULAY, Calum, E. [CA/CA]; 338 East 37th, Vancouver, British Columbia V5W 1E7 (CA). PALCIC, Branko [CA/CA]; 3758 Quesnel Drive, Vancouver, British Columbia V5W 1E7 (CA). McLEAN, David, I. [CA/CA]; 1246 West 26th Avenue, Vancouver, British Columbia V6H 2A9 (CA).</p> <p>(74) Agents: NASSIF, Omar, A. et al.; Gowling, Strathy &amp; Henderson, Suite 4900, Commerce Court West, Toronto, Ontario M5L 1J3 (CA).</p>   |  | <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b><br/> <i>With international search report.</i><br/> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> |   |
| <p>(54) Title: FLUORESCENCE SCOPE SYSTEM FOR DERMATOLOGIC DIAGNOSIS</p> <p>(57) Abstract</p> <p>Apparatus for the diagnosis of a skin disease site (3) by visual fluorescence inspection comprising an excitation light source (1) for illuminating the disease site (3), a light guide (2) for transmitting the excitation light directly to the disease site to generate fluorescence light and viewing goggles (4) for processing the excitation light reflected and the fluorescence light emitted from the disease site to provide a fluorescence image of the disease site to a user. The fluorescence image is used to aid the medical assessment of skin conditions and the diagnosis of cutaneous diseases by supplementing the visual assessment of skin lesions made by the naked eye. The apparatus can be used in several modes of operation that permit the viewing of full color fluorescence images and enhanced two color images. The apparatus can also use image intensifying equipment (10) to amplify fluorescence light so that even very weak fluorescing objects can be seen. A method for acquiring and viewing the fluorescence images is also disclosed.</p> |  |  |   |
|   |  |  |   |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |                                       |    |   |    |                          |
|----|--------------------------|----|---------------------------------------|----|---|----|--------------------------|
| AL | Albania                  | ES | Spain                                 | LS | Lesotho                                   | SI | Slovenia                 |
| AM | Armenia                  | FI | Finland                               | LT | Lithuania                                 | SK | Slovakia                 |
| AT | Austria                  | FR | France                                | LU | Luxembourg                                | SN | Senegal                  |
| AU | Australia                | GA | Gabon                                 | LV | Latvia                                    | SZ | Swaziland                |
| AZ | Azerbaijan               | GB | United Kingdom                        | MC | Monaco                                    | TD | Chad                     |
| BA | Bosnia and Herzegovina   | GE | Georgia                               | MD | Republic of Moldova                       | TG | Togo                     |
| BB | Barbados                 | GH | Ghana                                 | MG | Madagascar                                | TJ | Tajikistan               |
| BE | Belgium                  | GN | Guinea                                | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan             |
| BF | Burkina Faso             | GR | Greece                                | ML | Mali                                      | TR | Turkey                   |
| BG | Bulgaria                 | HU | Hungary                               | MN | Mongolia                                  | TT | Trinidad and Tobago      |
| BJ | Benin                    | IE | Ireland                               | MR | Mauritania                                | UA | Ukraine                  |
| BR | Brazil                   | IL | Israel                                | MW | Malawi                                    | UG | Uganda                   |
| BY | Belarus                  | IS | Iceland                               | MX | Mexico                                    | US | United States of America |
| CA | Canada                   | IT | Italy                                 | NE | Niger                                     | UZ | Uzbekistan               |
| CF | Central African Republic | JP | Japan                                 | NL | Netherlands                               | VN | Viet Nam                 |
| CG | Congo                    | KE | Kenya                                 | NO | Norway                                    | YU | Yugoslavia               |
| CH | Switzerland              | KG | Kyrgyzstan                            | NZ | New Zealand                               | ZW | Zimbabwe                 |
| CI | Côte d'Ivoire            | KP | Democratic People's Republic of Korea | PL | Poland                                    |    |                          |
| CM | Cameroon                 | KR | Republic of Korea                     | PT | Portugal                                  |    |                          |
| CN | China                    | KZ | Kazakhstan                            | RO | Romania                                   |    |                          |
| CU | Cuba                     | LC | Saint Lucia                           | RU | Russian Federation                        |    |                          |
| CZ | Czech Republic           | LI | Liechtenstein                         | SD | Sudan                                     |    |                          |
| DE | Germany                  | LK | Sri Lanka                             | SE | Sweden                                    |    |                          |
| DK | Denmark                  | LR | Liberia                               | SG | Singapore                                 |    |                          |
| EE | Estonia                  |    |                                       |    |   |    |                          |

## FLUORESCENCE SCOPE SYSTEM FOR DERMATOLOGIC DIAGNOSIS

### CROSS REFERENCE TO RELATED APPLICATION

This application claims priority from Canadian Patent Application No. 2,192,036, filed December 4, 1996, which application is hereby incorporated by reference in its entirety.

### FIELD OF THE INVENTION

This invention relates to a method and apparatus for viewing fluorescence emissions from skin disease sites to assist in diagnosis of the site.

### BACKGROUND OF THE INVENTION

Currently, the clinical diagnosis of skin disease is generally accomplished by visual inspection under white light illumination. In this process, the reflectance pattern of a skin lesion is examined. Visual diagnosis alone may not be particularly accurate for the early detection of skin cancer since many skin conditions have a similar appearance under white light. Therefore, when a suspect lesion is identified by visual examination, a biopsy is often performed for a definitive diagnosis. Not only is it crucial to diagnose skin pre-cancer or cancer at its early stage when it is curable, it is also important to improve the clinical diagnosis of suspect skin lesions so as to avoid unnecessary skin biopsies.

Several approaches have been tried to improve dermatologic diagnosis. Digital processing of reflectance images has been intensively investigated recently. Although reflectance imaging has led to improvements in registration, recording, and documentation of skin lesions, there has been little improvement in the diagnostic accuracy. The foregoing approach does not provide any additional data to the physician making the visual assessment because it is still based on the reflectance pattern of a lesion under white light illumination which is essentially the same pattern a human observer sees.

An alternative approach is ultraviolet UV or infrared IR photography which extends the visual perception of a physician to UV or IR reflectance patterns. However, the inconvenience due to delays in film image processing renders this technique impractical for everyday use.

5       A further alternative approach that is already in widespread medical use involves a "Wood's lamp" which consists of a mercury discharge lamp equipped with a filter that absorbs visible light, and transmits UVA light with a 365 nanometer peak. When using this device to assist in skin diagnosis, the eye serves as both the detector and the long pass filter. The eye is not sensitive to UV light, but is sensitive to visible  
10      fluorescent light. The "Wood's lamp" must be used in a darkened room, where the physician can see an image of a fluorescing disease site. The "Wood's lamp" is useful for the diagnosis of skin conditions such as tinea capitis, tinea versicolor, erythrasma, and some pseudomonas infections, as well as aiding in the detection and diagnosis of hypopigmented lesions.

15      SUMMARY OF THE INVENTION

The apparatus and method of the present invention permit viewing of fluorescence emission images of skin to aid in the medical assessment of skin conditions and the diagnosis of cutaneous diseases by supplementing the visual assessment of skin lesions. Effectively, the apparatus and method of the present  
20      invention extend the vision of a physician to fluorescence images generated by any preselected UV wavelength light or visible wavelength light in order to assist in an accurate visual diagnosis.

Accordingly, the present invention provides apparatus for the diagnosis of a skin disease site by visual inspection comprising:

25      an excitation light source for illuminating the disease site;  
            means for transmitting the excitation light directly to the disease site to generate fluorescence light;

means for processing the excitation light reflected and the fluorescence light emitted from the disease site to provide a fluorescence image of the disease site to a user.

Using the apparatus of the present invention, both full color images and 5 optically enhanced two color images over two specific wavelength bands of a fluorescing site can be viewed by a physician. An image intensifier version of the apparatus allows the physician to view even very weakly fluorescing sites.

In a further aspect, the present invention provides a method of diagnosing a skin disease site in low ambient light environment by visual inspection 10 comprising the steps of:

illuminating the disease site with a preselected excitation light source to generate fluorescence light;

processing the excitation light reflected and the fluorescence light emitted from the disease site to generate processed fluorescence images; and

15 viewing and evaluating the processed fluorescence images to permit visual diagnosis of the disease site.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Aspects of the present invention are illustrated merely by way of example, in the accompanying drawings in which:

20 Figure 1 is a schematic diagram showing an embodiment of the apparatus of the present invention;

Figure 2 is a detail view of an embodiment of the present invention that uses spectacles;

25 Figure 3 is a detail view of an alternative embodiment that uses image intensifying means to enhance the fluorescence images transmitted to the user; and

Figure 4 is a table illustrating the visual appearance of three types of skin lesions when viewed under normal white light and using the apparatus and method of the present invention.

## DESCRIPTION OF THE PREFERRED EMBODIMENTS

Referring to Figure 1, there is shown a schematic block diagram of a preferred embodiment of the apparatus of the present invention useful for dark room diagnosis of a skin disease site 3 by visual inspection. The apparatus includes an 5 excitation light source 1 for illuminating disease site 3 and a light guide 2 for transmitting the excitation light directly to the disease site in order to generate fluorescence light. The apparatus also includes means for processing the reflected excitation light and the emitted fluorescence light from the disease site in the form of binocular viewing apparatus 4 adapted to be worn by a user such that fluorescence 10 images are transmitted to the user's eyes 5. The foregoing apparatus is best operated under low ambient light conditions so as to minimize interference with the relatively weak fluorescence signals.

Light source 1 is selected to provide excitation light (either ultraviolet or visible light) for the disease site. The excitation light is conducted by light guide 2 to 15 illuminate the skin at the disease site of a patient. Endogenous fluorophores such as tryptophan, collagen cross-links, collagen, elastin, NADH and others in the illuminated skin tissue are excited by the photons of the excitation light and emit fluorescence light. This fluorescence light is processed by the binocular viewing apparatus 4 for viewing by both eyes 5 of the user. The fluorescence emissions from the skin are very sensitive 20 to the composition and structural changes of the tissue under examination. Different skin diseases or different prognostic stages of one lesion may show different composition and structural changes. Therefore, the cutaneous fluorescence emissions that the apparatus of the present invention permits to be observed provide more information about the skin under examination than would reflected light patterns under 25 white light. Thus, using the apparatus of the present application to perform fluorescence examination of the disease site in combination with conventional white light reflectance examination will permit better diagnostic accuracy.

Light source 1 is selected to provide excitation light that will generate tissue fluorescence. For example, a laser source such as a helium-cadmium (He-Cd) 30 laser provides 442 nm blue light that generates fluorescence. Alternatively, a Mercury

arc lamp light source can be used which provides UV and visible light at specific wavelengths, for example, a 365 nm UV line, a 405 nm blue line and a 436 nm blue line. Other types of lamp light sources may be used, such as a Wood's lamp, for illumination.

5 When a laser is used as a light source 1, light guide 2 is preferably an optic fiber. It has been determined that a fiber with a core diameter of about 400 µm and a micro lens attached at the fiber end adjacent the disease site works well as a light guide. Laser light is easily focused into the fiber and the microlens generates a uniform illumination spot. The diameter of the spot can be varied by changing the distance  
10 between the microlens tip and the skin surface.

If the light source is a Mercury arc lamp or other arc lamp such as a Xenon or metal halide arc lamp, an optic fiber bundle or liquid light guide of approximately 5 mm diameter is preferable as the light guide since it is impractical to focus light from an arc lamp into a single fiber. A 5 mm diameter fiber bundle or liquid  
15 light guide is adequate to capture sufficient light from the source for transmission to the disease site. A liquid light guide has better transmittance than a fiber bundle and thus more light is transmitted by a liquid light guide. However, this advantage is offset by the greater expense of the liquid light guide. The diameter of the light spot is varied in a similar manner as with the optic fiber by varying the distance between the end of the  
20 light guide and the skin surface.

Illumination may also be achieved without using a light guide. For example, LED (light emitting diode) panels and UV fluorescent lamps such as a Wood's lamp can be used to directly illuminate the skin.

An example of a binocular viewing apparatus 4 is shown in Figure 2 and  
25 comprises eye glass frames 20 with special light filters 6 and 7 mounted in either side of the frames to allow the transmission of an independent fluorescence image to each eye of the user. In an alternative arrangement, binocular viewing apparatus 4 comprises a set of goggles (not shown) to house light filters 6 and 7. The eye glass frames are preferably worn by users who do not normally wear eye glass, while the goggles  
30 arrangement can be worn over a user's conventional eye glasses.

There are a number of arrangements of light filters 6 and 7 in the apparatus of the present invention.

In a first embodiment, filters 6 and 7 are identical long pass filters selected to block the shorter wavelength excitation light and pass the longer wavelength emitted fluorescence light for viewing. In this manner, a full color fluorescence image of the disease site is transmitted to the user. By way of example, if a 442 nm He-Cd laser is used as light source 1 for fluorescence excitation, a 475 nm long pass filter (Scott glass GG475) can be used as filters 6 and 7.

In a second embodiment, filters 6 and 7 are selected to provide an enhanced two color image of the fluorescing disease site to the eyes of the user. Filters 6 and 7 are two different band pass filters, each filter being chosen to block the short wavelength excitation light and pass longer wavelength fluorescence light with set efficiencies for different wavelength bands to each eye. Therefore, each eye 5 sees an image of the fluorescing disease site in a color determined by the band pass filter in front of the particular eye. In addition to being different colors, the two images seen by the two eyes have different fluorescence intensity distributions. It has been determined experimentally that the brain of a user is able to compose the individual color images observed by each eye to form a single two color image of the fluorescing disease site that contains information in respect of the intensity variation and the color variation of the disease site as compared to the surrounding normal skin. The composed color at a particular location in the image is determined by the ratio of the integral fluorescence intensities over the two selected wavelength bands passed by filters 6 and 7. Therefore, the composed image perceived by the brain when using the apparatus of the present embodiment is a two dimensional distribution of the fluorescence intensity and the fluorescence ratio over two different wavelength bands. It is an enhanced two color image of the fluorescing disease which provides valuable information for skin disease diagnosis. Our studies have shown that the wavelength bands of filters 6 and 7 can be selected in response to fluorescence spectral studies of diseased skin to provide characteristic two color images that permit accurate diagnosis of a disease site condition.

In a third embodiment, filters 6 and 7 comprise two identical customised band pass filters, each filter being designed to block the excitation light and pass the emitted fluorescence light in at least two preselected wavelength bands. The two wavelength bands passed by filter 6 are identical to the two bands passed by filter 7 so

5 that the viewing apparatus of the third embodiment permits the examination of two color enhanced fluorescence images as described above in relation to the second embodiment. The image perceived by the brain using the customised identical filters of the present embodiment is identical to the image perceived when using the two different band pass filters of the second embodiment.

10 Although the binocular viewing apparatus 4 of the second and third embodiments provide the same information regarding a disease site under examination, each embodiment has its own advantages and disadvantages. The different band pass filters 6 and 7 used in the second embodiment are easy to design and make. The disadvantage with using the two different band pass filters is that each eye is shown a

15 different image and some training is necessary for a user to become comfortable with mentally combining the two different images. This is similar to the training that is necessary in order to view prepared photographs using special viewing glasses and be able to perceive a three dimensional image. In contrast, the disadvantage of using the same customised band pass filters in the third embodiment is that the filters are more

20 difficult to design and manufacture and hence much more expensive. However, using a viewing apparatus fitted with the customised filters requires no special training as the same two color image is transmitted to each eye. Both eyes see both wavelength bands, and, therefore, the brightness of the perceived image will be approximately twice that perceived using the viewing apparatus of the second embodiment where each eye sees

25 only one of the two wavelength bands.

Figure 3 is a schematic view of a further embodiment of the present invention involving another variation in the viewing apparatus 4. In this case, the viewing apparatus is provided with image intensifying means associated with the light filters comprising image intensifier 10 and 11. The principle of operation is the same as

30 with the second embodiment of the viewing apparatus except that image intensifiers 10

and 11 are used to amplify the fluorescence light so that very faint fluorescing disease sites can be viewed.

The intensified viewing apparatus comprises a pair of tubular housings mounted in a binocular frame for presenting simultaneous images to each eye. Each 5 tubular housing comprises a band pass filter 6 or 7, a first lens 8 or 9, an image intensifier 10 or 11, a second lens 12 or 13 and a final filter 14 or 15. Fluorescence light from the disease site is filtered by filters 6 or 7 which are preferably two different band pass filters. The filtered fluorescence light is then focused by lens 8 or 9 to form an image on the photocathode of the image intensifier 10 or 11. As is conventional, the 10 photocathode converts photons into electrons. The number of electrons corresponding to each image pixel is then multiplied by a multi-channel microplate with high voltages at its two ends. The multiplied electrons exit from the microplate and collide with a phosphor screen to form an optical image again. Lens 12 or 13 focuses the images for transmittal to the eye. Filter 14 or 15 provides a means to adjust the color of the image 15 presented to the eye. In combination with filter 14 or 15, different colored phosphors can be used in each of the phosphor screens of the image intensifiers 10 or 11 to create different colored images that are presented to each eye. In this manner, an optically enhanced two color image of the fluorescing disease site is presented to the two eyes of the user. As described previously, the two images are composed by the brain and 20 perceived as a two dimensional distribution of the fluorescing intensity and the fluorescence ratio over two different wavelength bands.

In association with the intensified viewing apparatus, light source 1 can be a pulsed source (flash lamp or pulsed laser), and intensifiers 10 and 11 can be gated to acquire images only when the skin is being exposed to the light pulses. An intense 25 pulse light source with pulse width in the microsecond to nanosecond domain will generate cutaneous fluorescence that is much brighter than the ambient light. The image intensifiers are gated on during this period to acquire the fluorescence image. Outside of the pulse duration, the intensifiers are gated off, and the ambient reflected light images are not acquired. In this way, the cutaneous fluorescence images can be 30 viewed with the ambient light on.

In order to demonstrate the use of the apparatus and method of the present invention, Figure 4 is provided. Figure 4 is a table showing in columns the visual appearance of three types of skin conditions, seborrheic keratosis, compound nevus and basal cell carcinoma, when viewed under different light. Each row of the 5 table shows the skin conditions under a different light condition.

The first row is the reflectance images under white light of the three skin sites. These images show substantially what a physician sees with the naked eye. All three skin conditions can appear substantially the same: a reddish, brown area surrounded by generally white skin. Distinguishing between the various conditions is 10 sometimes difficult.

Row 2 and 3 show the appearance of the skin lesions and their surrounding skin when view using 442 nm He-Cd laser excited fluorescence light. It is apparent that the coloring of the various lesions tends to be distinctive which greatly aids a user in differential diagnosis of the three different lesions.

15 Row 4 of Figure 4 shows the fluorescence spectra, fluorescence wavelength plotted against fluorescence intensity, for the disease sites illuminated by the 442 nm He-Cd laser.

Row 2 contains full color fluorescence images of the sites using the apparatus of the first embodiment of the present invention where filters 6 and 7 are 20 identical 475 nm long pass filters. The full color fluorescence images all have a yellowish background (normal skin). The seborrheic keratosis looks bright yellow since its spectrum has a higher intensity surrounding normal skin (see row 4). Both the compound nevus and bagel cell carcinoma look darker than the surrounding skin since their spectra have lower intensities than the surrounding skin. Therefore, the full color 25 fluorescence images are useful for differentiating the seborrheic keratosis from the other two lesions.

In row 3, the images are optically enhanced two color images acquired using the apparatus of the second or third embodiments or the image intensified apparatus. In this particular example, the two wavelength bands selected are green 30 (480 nm to 560 nm) and red (620 nm to 700 nm). The two color images have a greenish

background identifying normal skin. The seborrheic keratosis looks bright green since its spectrum has higher intensities in the green band than surrounding normal skin. The transmittance of the two wavelength bands are selected so that the basal cell carcinoma looks reddish, the compound nevus looks dark grey and normal skin appears greenish.

5 This is due to the fact that the ratio of the spectral maximum intensity of normal skin to that of the compound nevus is 4 while the ratio for basal cell carcinoma is 3.

The images of Figure 4 are only a few examples of the differential diagnosis capabilities of the apparatus and method of the present invention which provide new information for skin diagnosis.

10 The present invention provides a number of important technical advantages that can be summarised as follows:

1. The apparatus of the present invention provides new information for skin diagnosis as compared to conventional white light examination.
2. In comparison to a Wood's lamp, different excitation wavelengths including visible light can be used for fluorescence examination. The enhanced two color fluorescence examination mode is a totally different mode than Wood's lamp, and it enhances the color ratio over two wavelength bands to provide more powerful discrimination capabilities.
3. The image intensified embodiment of the present invention allows very weak fluorescing disease sites to be viewed and diagnosed.
4. The apparatus of the present invention are relatively inexpensive and easy to use.
5. The apparatus and method of the present invention provides a new, non-invasive system for performing more accurate dermatologic diagnosis.

25 Although the present invention has been described in some detail by way of example for purposes of clarity and understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims.

## CLAIMS

WE claim:

1. A binocular viewing apparatus comprising a frame adapted to be worn on the head of a user, the frame comprising first and second light filters mounted on either side of the frame, the first filter positioned to transmit a first independent fluorescence image to a first eye of the user and the second filter positioned to transmit a second independent fluorescence image to a second eye of the user, wherein each filter blocks at least light having a wavelength of about 442 nm or less.
2. Apparatus as claimed in claim 1 in which the frame is an eyeglass frame.
3. Apparatus as claimed in claim 1 in which the frame is a goggle frame.
4. Apparatus as claimed in claim 1 in which the first and second light filters comprise two identical light filters.
5. Apparatus as claimed in claim 4 in which the two identical light filters are long pass filters that block light having a wavelength of less than about 475 nm.
6. Apparatus as claimed in claim 5 in which the two identical light filters comprise band pass filters, each filter blocking light having a wavelength of less than about 475 nm and passing the fluorescence light in at least two selected wavelength bands.
7. Apparatus as claimed in claim 6 in which the at least two selected wavelength bands are green light and red light.

8. Apparatus as claimed in claim 7 in which the green light is from about 480 nm to about 560 nm and the red light is from about 620 nm to about 700 nm.

9. Apparatus as claimed in claim 1 in which the two or more light filters comprise two different light filters.

10. Apparatus as claimed in claim 9 in which the two different light filters comprise first and second band pass filters, the first band pass filter passing fluorescence light at a first wavelength band to one eye and the second band pass filter passing fluorescence light at a different wavelength band to the other eye.

11. Apparatus as claimed in claim 1 in which the apparatus further comprises at least one image intensifier that intensifies the light passing through at least one of the first and second light filters.

12. Apparatus as claimed in claim 11 in which the apparatus further comprises at least two image intensifiers, one for each of the first and second light filters.

13. Apparatus as claimed 12 in which the first and second light filters comprise first and second band pass filters, the first band pass filter passing fluorescence light at a first wavelength band to the first image intensifier and the second band pass filter passing fluorescence light at a second wavelength band to the second image intensifier.

14. Apparatus as claimed in claim 13 further comprising an adjuster that adjusts the color of the fluorescence image transmitted to each eye.

15. Apparatus as claimed in claim 14 in which the adjuster comprises color filters located between the image intensifiers and the eyes of the user.

16. Apparatus as claimed in claim 1 in which the apparatus further comprises an excitation light source attached to the frame, the excitation light source able to induce fluorescence in human skin in front of the first and second light filters.

17. Apparatus as claimed in claim 16 in which the apparatus further comprises a light guide that transmits the excitation light from the excitation light source to the skin.

18. Apparatus as claimed in claim 16 in which the excitation light source comprises a laser light source.

19. Apparatus as claimed in claim 16 in which the excitation light source comprises an arc lamp selected from the group consisting of a Mercury arc lamp, a Xenon arc lamp, and a metal halide lamp.

20. Apparatus as claimed in claim 16 in which the excitation light source is selected from the group consisting of a LED panel and a fluorescent UV lamp for direct illumination of the skin.

21. Apparatus as claimed in claim 16 in which the apparatus further comprises at least one image intensifier that intensifies the light passing through at least one of the first and second light filters.

22. Apparatus as claimed in claim 21 in which the excitation light source comprises a pulsed light source and the at least one image intensifier acquires an image only when the pulsed light source is activated.

23. Apparatus as claimed in claim 17 in which the light guide comprises an optic fiber having a microlens on an end of the fiber located near the skin.

24. Apparatus as claimed in claim 23 in which the light guide comprises an optic fiber bundle.

25. Apparatus as claimed in claim 23 in which the light guide comprises a liquid light guide.

26. Apparatus for diagnosis of skin disease sites by visual fluorescence inspection comprising:

an excitation light source for illuminating the disease site;

means for transmitting the excitation light directly to the disease site to generate fluorescence light; and

means for processing the excitation light reflected and the fluorescence light emitted from the disease site to provide a fluorescence image of the disease site to a user.

27. Apparatus as claimed in claim 26 in which the means for processing the light comprises:

two or more light filters;

binocular frames to receive the two or more light filters, the filters being arranged in the frames to transmit an independent fluorescence image to each eye of the user.

28. Apparatus as claimed in claim 27 in which the binocular frames are eyeglass frames.

29. Apparatus as claimed in claim 27 in which the binocular frames are goggle frames.

30. Apparatus as claimed in claim 27 in which the two or more light filters comprise two identical light filters.

31. Apparatus as claimed in claim 30 in which the two identical light filters are long pass filters that block the excitation light and pass the fluorescence light.

32. Apparatus as claimed in claim 30 in which the two identical light filters comprise band pass filters, each filter blocking the excitation light and passing the fluorescence light in at least two preselected wavelength bands.

33. Apparatus as claimed in claim 27 in which the two or more light filters comprise two different light filters.

34. Apparatus as claimed in claim 33 in which the two different filters comprise first and second band pass filters that both block the excitation light, the first band pass filter passing fluorescence light at a first wavelength band pass to one eye and the second band pass filter passing fluorescence light at a different wavelength band pass to the other eye.

35. Apparatus as claimed in claim 27 in which the means for processing the light includes image intensifying means associated with the two or more light filters.

36. Apparatus as claimed in claim 35 further comprising an adjuster that adjusts the color of the fluorescence image transmitted to each eye.

37. Apparatus as claimed in claim 36 in which the adjuster comprises color filters located between the image intensifiers and the eyes of the user.

38. Apparatus as claimed in claim 26 in which the excitation light source comprises a pulsed light source and the image intensifying means acquires an image only when the pulsed light source is activated.

39. A method of evaluating a potential human skin disease site by visual inspection comprising the steps of:

illuminating the disease site with a excitation light under conditions suitable and for a time sufficient to generate fluorescence light in the skin disease site;

passing the fluorescence light through at least one light filter mounted in a binocular frame that is disposed on the head of a user, the at least one filter blocking at least light having a wavelength of about 442 nm or less, thereby blocking the excitation light reflected from the disease site, and transmitting the fluorescence light emitted from the disease site to the eyes of the user to provide a transmitted fluorescence image; and

viewing and evaluating the transmitted fluorescence image.

40. A method as claimed in claim 39 in which the transmitted fluorescence image is produced by filtering through long pass filters and the disease site is viewed in full color.

41. A method as claimed in claim 39 in which the transmitted fluorescence image is produced by filtering through at least one band pass filter designed to transmit at least two different wavelength bands such that the disease site is viewed in at least two colors.

42. A method as claimed in claim 41 in which the at least two different wavelength bands are green light and red light.

43. A method as claimed in claim 42 in which the green light is from about 480 nm to about 560 nm and the red light is from about 620 nm to about 700 nm.

44. A method as claimed in claim 39 in which the at least one filter comprises first and second filters mounted on either side of the binocular frame, the first filter positioned to transmit a first independent fluorescence image to a first eye of the user and the second filter being different from the first filter and positioned to transmit a second independent fluorescence image to a second eye of the user, wherein the step of passing the

fluorescence light comprises passing the fluorescence light through the first and second filters, thereby providing two different transmitted fluorescence images.

45. A method as claimed in claim 45 in which each of the processed fluorescence images is produced by filtering through different band pass filters such that the disease site is viewed in two colors.

46. A method as claimed in claim 39 in which the step of passing the fluorescence light through the at least one filter comprises the additional step of transmitting the fluorescence light through an image intensifier to amplify the fluorescence light.

1/3




Fig. 1

2/3




Fig. 2




Fig. 3

3/3




Fig. 4

# INTERNATIONAL SEARCH REPORT

Int'l. Application No  
PCT/CA 97/00919

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61B5/00 A61B5/103

According to International Patent Classification(IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No.   |
|----------|--|-------------------------|
| P, X     | WO 96 39925 A (UNIVERSITY OF ARKANSAS) 19 December 1996                            | 1-6, 11                 |
| X        | see page 3, line 33 - page 4, line 17  | 12, 16                  |
| X        | see page 14, line 9 - page 16, line 17   | 18, 21                  |
| X        | see page 5, line 10 - page 6, line 32  | 26-32, 35               |
| P, X     | EP 0 783 867 A (UNILEVER PLC ET AL) 16 July 1997                                   | 1-9,<br>26-34           |
| A        | see column 3, line 3 - line 38   | 10-21, 35               |
| A        | see column 4, line 13 - column 6, line 18  | 10-21, 35               |
| X        | EP 0 113 152 A (NORTH AMERICAN PHILIPS CORPORATION) 11 July 1984                   | 1-6,<br>26-32           |
| A        | see page 2, line 17 - line 31  | 7, 8, 17,<br>19, 23, 24 |
|          | see page 4, line 4 - line 34   |                         |
|          | ---  |                         |
|          | -/-  |                         |

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

**' Special categories of cited documents :**

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

20 April 1998

Date of mailing of the international search report

27.04.98

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Geffen, N

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 97/00919

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication where appropriate, of the relevant passages                             | Relevant to claim No.        |
|----------|---|------------------------------|
| X        | WO 96 08201 A (CEDARS-SINAI MEDICAL CENTRE) 21 March 1996<br>see page 4, line 3 - page 5, line 16             | 26                           |
| A        | see page 8, line 27 - page 11, line 29  | 1,5-10<br>17,18,<br>20,23,24 |
|          | ---   |                              |
| X        | WO 94 16622 A (COMPUTER AIDED MEDICAL INC U.S.A. INC.) 4 August 1994<br>see page 5, line 13 - page 8, line 27 | 26                           |
| Y        | see page 12, line 31 - page 13, line 15   | 1-6,9<br>10,27-34            |
| Y        | see page 14, line 13 - page 15, line 5  | 36,37<br>7,8,14,<br>15,38    |
| A        | ---   |                              |
| Y        | WO 96 36273 A (THE UNITED STATES OF AMERICA) 21 November 1996<br>see page 8, line 6 - page 9, line 3          | 1-6,9,<br>10,27-34           |
| A        | see page 5, line 17 - page 7, line 14   | 36,37<br>11-13.<br>21,26,35  |
|          | -----   |                              |

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No  
PCT/CA 97/00919

| Patent document cited in search report | Publication date | Patent family member(s) |  | Publication date |
|--|------------------|-------------------------|--|------------------|
| WO 9639925 A                           | 19-12-96         | AU 5929696 A            |  | 30-12-96         |
|  |                  | EP 0830077 A            |  | 25-03-98         |
| EP 0783867 A                           | 16-07-97         | CA 2186333 A            |  | 22-06-97         |
|  |                  | JP 9173048 A            |  | 08-07-97         |
| EP 0113152 A                           | 11-07-84         | JP 59137037 A           |  | 06-08-84         |
| WO 9608201 A                           | 21-03-96         | US 5701902 A            |  | 30-12-97         |
| WO 9416622 A                           | 04-08-94         | AU 6230994 A            |  | 15-08-94         |
|  |                  | ZA 9400343 A            |  | 26-08-94         |
| WO 9636273 A                           | 21-11-96         | AU 5665996 A            |  | 29-11-96         |

**THIS PAGE BLANK (USPTO)**